Thank you, Mark. As Mark alluded, we have successfully completed the first phase of the demonstrating project for tank waste at Hanford. The deal we recently announced at its Office of Environmental Management Office of River Protection in Richmond, Washington coordinated a shipment of approximately three gallons of low-activity tank waste to Perma-Fix Northwest. We subsequently treated and stabilized the waste from our facility for transportation and permanent disposal at the Waste Control Specialists, Federal Waste Disposal Facility in Andrews, Texas. For those of you that have been following the company for some time, participating in this project has been a long-term vision and goal of our company. This is the first time that EM has commercially treated, stabilized and shipped low-level waste derived from Hanford tank waste off-site to a commercial facility for disposal. This effort in part completes the initial phase of the plan three-phase DOE EM test bed initiative study. The process utilized for [indiscernible] was developed to reduce the complex cost for processing this waste stream based on our proven principles to treat the waste to meet disposal criteria. Now that we've completed the first phase of the demonstration, we are focusing our attention on the next phase of the test bed initiative, which requires a treatment of approximately 2000 gallons. And finally, on one final note, we have shifted our strategy within our medical subsidiary. Specifically, we are focusing our efforts around a new partnering strategy, which we believe will be much more cost effective and mitigate the need of waste capital near term at the subsidiary level. Raising capital now, as we have seen, will significantly dilute Perma-Fix's interest in subsidiary. But if we can hit certain milestones first, then raise capital, we believe we'll be able to do so much more under favorable terms. I'm happy to report since implementing this strategy, we're working with several groups, one in Canada, one in Italy and third in Poland that we've - is presently working under our Polish grant. They've indicated willingness to fund development and with regulatory costs in the respective markets. This strategy will help mitigate our short-term capital requirements, while providing further validation, accelerating our path to commercialization in international markets and helping streamline the path for eventual approval in the U.S.. The advantage of initially focusing our efforts in Europe and Canada as we believe is more streamlined, lower cost regulatory process. Once we have hit certain milestones, we'll then turn our attention back to the U.S. where we believe we can this markup [indiscernible] Negotiate a partnership for ourselves on much better terms. On that note, I'd like now to turn the call over to Ben, who will discuss the financial results in more detail.